NASDAQ:FLDM - Fluidigm Stock Price, Price Target & More

$6.14 +0.02 (+0.33 %)

(As of 04/23/2018 04:00 PM ET)

Previous Close$6.14

Today's Range$6.01 - $6.23

52-Week Range$2.52 - $8.38

Volume108,653 shs

Average Volume196,737 shs

Market Capitalization$237.53 million

P/E Ratio-5.16

Dividend YieldN/A

Beta2.99

About Fluidigm (NASDAQ:FLDM)

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell genomics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

Receive FLDM News and Ratings via Email

Sign-up to receive the latest news and ratings for FLDM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments

Sub-IndustryLife Sciences Tools & Services

SectorMedical

SymbolNASDAQ:FLDM

CUSIP34385P10

Webwww.fluidigm.com

Phone650-266-6000

Debt

Debt-to-Equity Ratio6.31%

Current Ratio2.83%

Quick Ratio2.38%

Price-To-Earnings

Trailing P/E Ratio-5.16

Forward P/E Ratio-6.60

P/E GrowthN/A

Sales & Book Value

Annual Sales$101.94 million

Price / Sales2.34

Cash FlowN/A

Price / CashN/A

Book Value$0.80 per share

Price / Book7.68

Profitability

EPS (Most Recent Fiscal Year)($1.19)

Net Income$-60,530,000.00

Net Margins-59.38%

Return on Equity-118.56%

Return on Assets-13.65%

Miscellaneous

Employees505

Outstanding Shares38,810,000

How to Become a New Pot Stock Millionaire

Fluidigm (NASDAQ:FLDM) Frequently Asked Questions

What is Fluidigm's stock symbol?

Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."

How were Fluidigm's earnings last quarter?

Fluidigm Co. (NASDAQ:FLDM) issued its quarterly earnings results on Thursday, February, 8th. The medical research company reported ($0.27) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.02. The medical research company earned $27.75 million during the quarter, compared to analyst estimates of $27.14 million. Fluidigm had a negative net margin of 59.38% and a negative return on equity of 118.56%. Fluidigm's revenue was up 10.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.32) earnings per share. View Fluidigm's Earnings History.

When is Fluidigm's next earnings date?

Fluidigm is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Fluidigm.

What price target have analysts set for FLDM?

1 analysts have issued 12 month price targets for Fluidigm's shares. Their predictions range from $6.10 to $6.10. On average, they anticipate Fluidigm's stock price to reach $6.10 in the next year. View Analyst Ratings for Fluidigm.

Who are some of Fluidigm's key competitors?

Some companies that are related to Fluidigm include Quanterix (QTRX), Pacific Biosciences (PACB), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), pSivida (EYPT), Aethlon Medical (AEMD), Arrayit (ARYC), Precipio (PRPO), Pressure BioSciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).

Who are Fluidigm's key executives?

Fluidigm's management team includes the folowing people:

Mr. Stephen Christopher Linthwaite, Pres, CEO & Director (Age 45)
Mr. Gajus V. Worthington, Co-Founder and Consultant (Age 48)
Mr. Vikram Jog, Chief Financial Officer (Age 62)
Mr. Nicholas S. Khadder, Sr. VP, Gen. Counsel & Corp. Sec. (Age 44)
Mr. Steven C. McPhail, Chief Commercial Officer (Age 64)

Has Fluidigm been receiving favorable news coverage?

Headlines about FLDM stock have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fluidigm earned a media sentiment score of 0.12 on Accern's scale. They also gave news stories about the medical research company an impact score of 45.99 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Fluidigm's major shareholders?

Fluidigm's stock is owned by a variety of of institutional and retail investors. Top institutional investors include LEVIN CAPITAL STRATEGIES, L.P. (32.20%) and PRIMECAP MANAGEMENT COMPANY (14.94%). Company insiders that own Fluidigm stock include Evan/ Fa Jones, Levin Capital Strategies, LP, Samuel D Colella, Stephen Christopher Linthwaite and Steven Mcphail. View Institutional Ownership Trends for Fluidigm.

How do I buy shares of Fluidigm?

Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fluidigm's stock price today?

One share of FLDM stock can currently be purchased for approximately $6.14.

How big of a company is Fluidigm?

Fluidigm has a market capitalization of $237.53 million and generates $101.94 million in revenue each year. The medical research company earns $-60,530,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fluidigm employs 505 workers across the globe.

How can I contact Fluidigm?

Fluidigm's mailing address is 7000 Shoreline Court Suite 100, South San Francisco CA, 94080. The medical research company can be reached via phone at 650-266-6000.

MarketBeat Community Rating for Fluidigm (FLDM)

Community Ranking:		3.2 out of 5 ( )
Outperform Votes:		352 (Vote Outperform)
Underperform Votes:		193 (Vote Underperform)
Total Votes:		545

MarketBeat's community ratings are surveys of what our community members think about Fluidigm and other stocks. Vote "Outperform" if you believe FLDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLDM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Fluidigm (NASDAQ:FLDM) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

1 Wall Street analysts have issued ratings and price targets for Fluidigm in the last 12 months. Their average twelve-month price target is $6.10, suggesting that the stock has a possible downside of 0.65%. The high price target for FLDM is $6.10 and the low price target for FLDM is $6.10. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Buy	Buy
Consensus Rating Score:	2.00	2.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$6.10	$6.10	$9.00	$9.00
Price Target Upside:	0.65% downside	5.54% upside	44.69% upside	44.69% upside

Fluidigm (NASDAQ:FLDM) Consensus Price Target History

Price Target History for Fluidigm (NASDAQ:FLDM)

Fluidigm (NASDAQ:FLDM) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/8/2018	Piper Jaffray	Reiterated Rating	Hold	$6.10	High
2/9/2017	Cantor Fitzgerald	Set Price Target	Buy	$9.00	N/A
8/5/2016	Mizuho	Boost Price Target	Buy	$11.00 -> $12.00	N/A
6/1/2016	Deutsche Bank	Initiated Coverage	Buy		N/A

(Data available from 4/23/2016 forward)

Fluidigm (NASDAQ:FLDM) Earnings History and Estimates Chart

Earnings by Quarter for Fluidigm (NASDAQ:FLDM)

Fluidigm (NASDAQ:FLDM) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.93 EPS
Next Year EPS Consensus Estimate: $-0.74 EPS

Fluidigm (NASDAQ FLDM) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/3/2018		($0.41)					N/A
2/8/2018	Q4 2017	($0.25)	($0.27)	$27.14 million	$27.75 million	View	Listen
11/2/2017	Q3 2017	($0.37)	($0.31)	$25.50 million	$24.75 million	View	N/A
8/3/2017	Q2 2017	($0.60)	($0.58)	$23.50 million	$23.90 million	View	Listen
5/4/2017	Q1 2017	($0.64)	($0.41)	$25.00 million	$25.53 million	View	N/A
2/8/2017	Q4 2016	($0.61)	($0.61)	$25.91 million	$25.10 million	View	Listen
11/3/2016	Q3	($0.67)	($0.68)	$27.75 million	$22.20 million	View	N/A
8/4/2016	Q2	($0.58)	($0.64)	$29.62 million	$28.20 million	View	N/A
5/5/2016	Q116	($0.53)	($0.40)	$26.95 million	$29.00 million	View	N/A
2/4/2016	Q4 2015	($0.48)	($0.38)	$30.10 million	$30.72 million	View	N/A
10/29/2015	Q315	($0.55)	($0.15)	$27.54 million	$28.60 million	View	Listen
8/6/2015	Q215	($0.48)	($0.53)	$30.43 million	$28.62 million	View	Listen
5/7/2015	Q115	($0.40)	($0.39)	$30.70 million	$26.70 million	View	Listen
2/5/2015	Q414	($0.43)	($0.39)	$33.34 million	$33.50 million	View	Listen
10/30/2014	Q314	($0.04)	($0.49)	$29.20 million	$29.60 million	View	N/A
7/31/2014	Q214	($0.50)	($0.45)	$27.13 million	$27.60 million	View	N/A
5/5/2014	Q1 2014	($0.31)	($0.19)	$21.01 million	$25.72 million	View	N/A
2/6/2014	Q413	($0.15)	($0.04)	$20.73 million	$20.90 million	View	N/A
10/30/2013	Q313	($0.20)	($0.06)	$16.70 million	$18.30 million	View	N/A
8/1/2013	Q2 2013	($0.17)	($0.07)	$15.87 million	$17.50 million	View	N/A
5/1/2013	Q1 2013	($0.21)	($0.21)	$14.49 million	$14.54 million	View	N/A
2/12/2013	Q4 2012	($0.15)	($0.14)			View	N/A
11/7/2012	Q312	($0.21)	($0.12)	$13.35 million	$12.60 million	View	N/A
8/7/2012	Q2 2012	($0.25)	($0.22)			View	N/A
5/10/2012	Q1 2012	($0.26)	($0.25)			View	N/A
2/14/2012	Q4 2011	($0.21)	($0.17)			View	N/A
11/8/2011	Q3 2011	($0.23)	($0.22)			View	N/A
8/9/2011	Q2 2011	($0.22)	($0.21)			View	N/A
5/10/2011	Q1 2011	($0.28)	($0.35)			View	N/A
3/9/2011	Q4 2010		($1.25)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Fluidigm (NASDAQ:FLDM) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Fluidigm (NASDAQ FLDM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 95.03%

Insider Trading History for Fluidigm (NASDAQ:FLDM)

Fluidigm (NASDAQ FLDM) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/2/2018	Levin Capital Strategies, L.P.	Insider	Buy	7,240	$5.73	$41,485.20
3/26/2018	Levin Capital Strategies, L.P.	Insider	Buy	21,020	$5.83	$122,546.60
3/23/2018	Levin Capital Strategies, L.P.	Insider	Buy	7,720	$5.97	$46,088.40
3/8/2018	Levin Capital Strategies, L.P.	Insider	Buy	40,000	$6.48	$259,200.00
3/5/2018	Levin Capital Strategies, L.P.	Insider	Buy	7,500	$6.17	$46,275.00
3/2/2018	Levin Capital Strategies, L.P.	Insider	Buy	250,355	$6.25	$1,564,718.75
2/28/2018	Levin Capital Strategies, L.P.	Insider	Buy	13,950	$6.82	$95,139.00
2/15/2018	Levin Capital Strategies, L.P.	Insider	Buy	10,000	$7.86	$78,600.00
2/7/2018	Levin Capital Strategies, L.P.	Insider	Buy	53,610	$5.73	$307,185.30
2/5/2018	Levin Capital Strategies, L.P.	Insider	Buy	50,987	$5.96	$303,882.52
2/1/2018	Levin Capital Strategies, L.P.	Insider	Buy	152,891	$6.18	$944,866.38
1/23/2018	Levin Capital Strategies, L.P.	Insider	Buy	6,871	$6.57	$45,142.47
1/16/2018	Levin Capital Strategies, L.P.	Insider	Buy	887	$6.68	$5,925.16
1/10/2018	Levin Capital Strategies, L.P.	Insider	Buy	100,576	$6.34	$637,651.84
1/3/2018	Levin Capital Strategies, L.P.	Insider	Buy	29	$6.63	$192.27
12/29/2017	Levin Capital Strategies, L.P.	Insider	Buy	11,230	$5.94	$66,706.20
12/28/2017	Levin Capital Strategies, L.P.	Insider	Buy	30	$5.82	$174.60
12/27/2017	Levin Capital Strategies, L.P.	Insider	Buy	27,100	$5.88	$159,348.00
12/15/2017	Levin Capital Strategies, L.P.	Insider	Buy	24,175	$5.84	$141,182.00
12/12/2017	Levin Capital Strategies, L.P.	Insider	Buy	18,569	$5.84	$108,442.96
12/4/2017	Levin Capital Strategies, L.P.	Insider	Buy	8,409	$5.48	$46,081.32
11/29/2017	Levin Capital Strategies, L.P.	Insider	Buy	20,380	$5.71	$116,369.80
11/17/2017	Levin Capital Strategies, L.P.	Insider	Buy	6,880	$5.05	$34,744.00
11/8/2017	Levin Capital Strategies, L.P.	Insider	Buy	54,900	$5.26	$288,774.00
10/25/2017	Levin Capital Strategies, L.P.	Insider	Buy	4,227	$5.42	$22,910.34
10/23/2017	Levin Capital Strategies, L.P.	Insider	Buy	22,363	$5.47	$122,325.61
10/19/2017	Levin Capital Strategies, L.P.	Insider	Buy	60,000	$4.55	$273,000.00
10/17/2017	Levin Capital Strategies, L.P.	Insider	Buy	144,200	$4.59	$661,878.00
10/10/2017	Levin Capital Strategies, L.P.	Insider	Buy	95,843	$4.57	$438,002.51
10/9/2017	Levin Capital Strategies, L.P.	Insider	Buy	50,000	$4.59	$229,500.00
9/12/2017	Levin Capital Strategies, L.P.	Insider	Buy	60,000	$5.25	$315,000.00
8/17/2017	Levin Capital Strategies, L.P.	Insider	Buy	465	$3.66	$1,701.90
8/10/2017	Levin Capital Strategies, L.P.	Insider	Buy	4,003,129	$3.30	$13,210,325.70
8/9/2017	Levin Capital Strategies, L.P.	Insider	Buy	1,549	$3.18	$4,925.82
8/8/2017	Samuel D Colella	Director	Buy	35,895	$2.77	$99,429.15	45,197
8/8/2017	Stephen Christopher Linthwaite	CEO	Buy	45,000	$2.66	$119,700.00	106,977
8/8/2017	Steven Mcphail	Insider	Buy	20,000	$3.00	$60,000.00	27,842
6/7/2017	Evan/ Fa Jones	Director	Sell	10,900	$4.54	$49,486.00
5/9/2017	Samuel D Colella	Director	Buy	7,500	$5.93	$44,475.00	43,523
3/14/2017	Samuel D Colella	Director	Buy	10,000	$5.00	$50,000.00	43,523
12/14/2016	Samuel D Colella	Director	Buy	5,000	$7.39	$36,950.00	44,123
11/30/2016	Samuel D Colella	Director	Buy	20,000	$6.32	$126,400.00	19,123
11/30/2016	Stephen Christopher Linthwaite	CEO	Buy	55,000	$6.36	$349,800.00	58,000
11/7/2016	Levin Capital Strategies, L.P.	Insider	Buy	159,200	$4.44	$706,848.00
11/2/2016	Levin Capital Strategies, L.P.	Insider	Buy	48,302	$4.44	$214,460.88
10/1/2015	Gajus Vincent Worthington	CEO	Sell	6,000	$8.05	$48,300.00	6,815
9/2/2015	Gajus Vincent Worthington	CEO	Sell	12,000	$11.53	$138,360.00	6,815
6/16/2015	Vikram Jog	CFO	Sell	3,550	$25.00	$88,750.00
6/15/2015	William Maxwell Smith	EVP	Sell	3,000	$24.20	$72,600.00
6/1/2015	Gajus Vincent Worthington	CEO	Sell	6,000	$23.71	$142,260.00
4/20/2015	Mai Chan Yow	Insider	Sell	15,300	$44.73	$684,369.00
4/17/2015	Mai Chan Yow	Insider	Sell	4,700	$44.04	$206,988.00
4/17/2015	William Maxwell Smith	EVP	Sell	3,000	$43.05	$129,150.00
4/8/2015	Mai Chan Yow	Insider	Sell	30,000	$42.67	$1,280,100.00
4/7/2015	Vikram Jog	CFO	Sell	3,950	$40.81	$161,199.50
4/1/2015	Gajus Vincent Worthington	CEO	Sell	6,000	$40.02	$240,120.00
4/1/2015	Robert C Jones	EVP	Sell	3,000	$41.63	$124,890.00
3/16/2015	William Maxwell Smith	EVP	Sell	3,000	$40.87	$122,610.00
3/9/2015	Vikram Jog	CFO	Sell	3,950	$41.48	$163,846.00
3/2/2015	Evan/ Fa Jones	Director	Sell	7,500	$44.15	$331,125.00
3/2/2015	Gajus Vincent Worthington	CEO	Sell	6,000	$43.77	$262,620.00
3/2/2015	Robert C Jones	EVP	Sell	3,000	$43.78	$131,340.00
2/20/2015	Samuel D Colella	Director	Sell	44,540	$38.97	$1,735,723.80
2/2/2015	Gajus Vincent Worthington	CEO	Sell	6,000	$38.15	$228,900.00
1/15/2015	William Maxwell Smith	EVP	Sell	3,000	$34.24	$102,720.00
1/2/2015	Gajus Vincent Worthington	CEO	Sell	6,000	$33.37	$200,220.00
12/15/2014	William Maxwell Smith	EVP	Sell	3,000	$27.20	$81,600.00
12/12/2014	Evan/ Fa Jones	Director	Sell	8,352	$27.44	$229,178.88
12/9/2014	Evan/ Fa Jones	Director	Sell	3,336	$28.34	$94,542.24
12/8/2014	Evan/ Fa Jones	Director	Sell	1,000	$29.06	$29,060.00
12/8/2014	Vikram Jog	CFO	Sell	3,950	$29.07	$114,826.50
12/1/2014	Gajus Vincent Worthington	CEO	Sell	6,000	$30.03	$180,180.00
11/17/2014	William Maxwell Smith	EVP	Sell	3,000	$29.52	$88,560.00
11/12/2014	Evan/ Fa Jones	Director	Sell	5,000	$29.55	$147,750.00
11/7/2014	Vikram Jog	CFO	Sell	3,950	$29.45	$116,327.50
10/24/2014	Mai Chan Yow	Insider	Sell	10,000	$28.00	$280,000.00
10/7/2014	Vikram Jog	CFO	Sell	3,950	$22.65	$89,467.50
9/15/2014	William Maxwell Smith	EVP	Sell	3,000	$30.83	$92,490.00
9/8/2014	Vikram Jog	CFO	Sell	3,950	$28.57	$112,851.50
9/2/2014	Gajus Vincent Worthington	CEO	Sell	6,000	$28.16	$168,960.00
8/7/2014	Vikram Jog	CFO	Sell	3,733	$26.34	$98,327.22
8/6/2014	Gajus Vincent Worthington	CEO	Sell	6,000	$26.53	$159,180.00
7/15/2014	William Maxwell Smith	EVP	Sell	3,000	$31.98	$95,940.00
7/7/2014	Vikram Jog	CFO	Sell	5,427	$30.61	$166,120.47
7/1/2014	Gajus Vincent Worthington	CEO	Sell	6,000	$29.72	$178,320.00
6/16/2014	William Maxwell Smith	EVP	Sell	3,000	$27.64	$82,920.00
6/2/2014	Gajus Vincent Worthington	CEO	Sell	6,000	$26.55	$159,300.00
5/15/2014	William Maxwell Smith	EVP	Sell	3,000	$28.53	$85,590.00
5/8/2014	Gajus Vincent Worthington	CEO	Sell	6,000	$32.14	$192,840.00
4/15/2014	William Maxwell Smith	EVP	Sell	3,000	$35.32	$105,960.00
4/7/2014	Vikram Jog	CFO	Sell	5,091	$37.51	$190,963.41
3/17/2014	William Maxwell Smith	EVP	Sell	3,000	$47.76	$143,280.00
11/6/2013	Gajus Vincent Worthington	CEO	Sell	11,832	$30.03	$355,314.96
9/3/2013	Gajus Vincent Worthington	CEO	Sell	10,000	$20.53	$205,300.00
9/3/2013	William Maxwell Smith	EVP	Sell	7,000	$20.42	$142,940.00
8/30/2013	Robert Jones	EVP	Sell	3,500	$20.36	$71,260.00
8/14/2013	Samuel Colella	Director	Sell	23,192	$19.91	$461,752.72	2,631
8/8/2013	William Maxwell Smith	EVP	Sell	16,000	$20.02	$320,320.00
8/6/2013	Gajus Vincent Worthington	CEO	Sell	10,000	$19.49	$194,900.00
8/6/2013	Robert Jones	EVP	Sell	3,500	$19.16	$67,060.00
7/8/2013	Vikram Jog	CFO	Sell	5,661	$17.05	$96,520.05
7/1/2013	Gajus Vincent Worthington	CEO	Sell	10,000	$17.14	$171,400.00
7/1/2013	William Maxwell Smith	EVP	Sell	5,000	$17.11	$85,550.00
6/28/2013	Robert C Jones	EVP	Sell	3,500	$17.11	$59,885.00
6/7/2013	Vikram Jog	CFO	Sell	5,661	$16.00	$90,576.00
6/3/2013	Gajus Vincent Worthington	CEO	Sell	10,000	$17.00	$170,000.00
6/3/2013	William Maxwell Smith	Insider	Sell	5,000	$16.96	$84,800.00
5/31/2013	Robert C Jones	EVP	Sell	3,500	$16.93	$59,255.00
3/4/2013	Mai Chan Yow	Insider	Sell	30,000	$18.15	$544,500.00
2/4/2013	Robert C Jones	EVP	Sell	6,984	$16.61	$116,004.24
2/1/2013	Gajus Vincent Worthington	CEO	Sell	10,000	$16.60	$166,000.00
12/28/2012	William Maxwell Smith	Insider	Sell	4,504	$14.11	$63,551.44
12/26/2012	William Maxwell Smith	Insider	Sell	6,756	$14.36	$97,016.16
12/14/2012	Evan/ Fa Jones	Director	Buy	10,000	$14.36	$143,600.00
12/11/2012	Evan/ Fa Jones	Director	Buy	1,971	$14.00	$27,594.00
12/5/2012	William Maxwell Smith	EVP	Sell	6,756	$14.25	$96,273.00

(Data available from 1/1/2013 forward)

Fluidigm (NASDAQ FLDM) News Headlines

Source:

Date	Headline
	Brad Kreger Joins Fluidigm as Senior Vice President, Global Operations finance.yahoo.com - April 23 at 8:51 AM
	Has Fluidigm Corporation (NASDAQ:FLDM) Improved Earnings Growth In Recent Times? finance.yahoo.com - April 20 at 9:14 AM
	Fluidigm to Report Q1 2018 Financial Results and Host Conference Call finance.yahoo.com - April 19 at 4:56 PM
	Fluidigm Introduces High-Parameter Maxpar Immune Monitoring Panel for Translational and Clinical Research finance.yahoo.com - April 13 at 4:48 PM
	Fluidigm Releases CFTR Next-Generation Sequencing Library Prep Assay for Use With the Juno System finance.yahoo.com - April 12 at 9:53 AM
	Fluidigm (FLDM) Upgraded to "Sell" at ValuEngine www.americanbankingnews.com - April 6 at 11:39 AM
	Levin Capital Strategies, L.P. Acquires 7,240 Shares of Fluidigm Co. (FLDM) Stock www.americanbankingnews.com - April 4 at 4:16 PM
	Comparing HTG Molecular Diagnostics (HTGM) & Fluidigm (FLDM) www.americanbankingnews.com - April 1 at 11:06 PM
	Head-To-Head Survey: Fluidigm (FLDM) versus BioSig Technologies (BSGM) www.americanbankingnews.com - March 31 at 5:16 AM
	Levin Capital Strategies, L.P. Buys 7,720 Shares of Fluidigm Co. (FLDM) Stock www.americanbankingnews.com - March 27 at 10:50 PM
	Levin Capital Strategies, L.P. Acquires 21,020 Shares of Fluidigm Co. (FLDM) Stock www.americanbankingnews.com - March 27 at 10:50 PM
	Fluidigm (FLDM) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - March 25 at 6:25 PM
	What Investors Should Know About Fluidigm Corporation’s (NASDAQ:FLDM) Financial Strength finance.yahoo.com - March 13 at 9:18 AM
	Levin Capital Strategies, L.P. Acquires 40,000 Shares of Fluidigm Co. (FLDM) Stock www.americanbankingnews.com - March 12 at 7:57 PM
	Fluidigm Co. (FLDM) Insider Purchases $46,275.00 in Stock www.americanbankingnews.com - March 6 at 9:58 PM
	Insider Buying: Fluidigm Co. (FLDM) Insider Purchases 250,355 Shares of Stock www.americanbankingnews.com - March 5 at 9:11 PM
	Fluidigm Announces Exchange of Convertible Notes finance.yahoo.com - March 2 at 9:01 AM
	Fuller & Thaler Asset Management Inc. Cuts Position in Fluidigm Co. (FLDM) www.americanbankingnews.com - March 2 at 7:00 AM
	Levin Capital Strategies, L.P. Acquires 13,950 Shares of Fluidigm Co. (FLDM) Stock www.americanbankingnews.com - March 1 at 10:28 PM
	What Should Investors Know About The Future Of Fluidigm Corporation’s (NASDAQ:FLDM) Business? finance.yahoo.com - February 27 at 5:19 PM
	BidaskClub Downgrades Fluidigm (FLDM) to Buy www.americanbankingnews.com - February 24 at 1:28 PM
	Levin Capital Strategies, L.P. Buys 10,000 Shares of Fluidigm Co. (FLDM) Stock www.americanbankingnews.com - February 20 at 9:46 PM
	Fluidigm (FLDM) Raised to "Strong-Buy" at BidaskClub www.americanbankingnews.com - February 19 at 3:56 PM
	Fluidigm to Participate in Upcoming Health Care Investor Conferences finance.yahoo.com - February 14 at 5:00 PM
	Free Post Earnings Research Report: Thermo Fisher’s Quarterly Revenue Surged 22%; Adjusted EPS Advanced 16% finance.yahoo.com - February 14 at 9:24 AM
	Fluidigm Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Progress finance.yahoo.com - February 9 at 9:26 AM
	Piper Jaffray Companies Reaffirms "Hold" Rating for Fluidigm (FLDM) www.americanbankingnews.com - February 9 at 12:54 AM
	Fluidigm (FLDM) Releases Earnings Results, Beats Expectations By $0.17 EPS www.americanbankingnews.com - February 9 at 12:52 AM
	Is Fluidigm Corporation (NASDAQ:FLDM) Undervalued? finance.yahoo.com - February 8 at 4:10 PM
	Fluidigm Co. (FLDM) Insider Buys $307,185.30 in Stock www.americanbankingnews.com - February 8 at 3:16 PM
	Levin Capital Strategies, L.P. Purchases 50,987 Shares of Fluidigm Co. (FLDM) Stock www.americanbankingnews.com - February 7 at 12:16 AM
	Fluidigm Co. (FLDM) Insider Levin Capital Strategies, L.P. Acquires 152,891 Shares www.americanbankingnews.com - February 2 at 6:16 PM
	Fluidigm (FLDM) to Release Earnings on Thursday www.americanbankingnews.com - February 1 at 1:06 AM
	Fluidigm to Report Q4 and Full Year 2017 Financial Results finance.yahoo.com - January 25 at 4:12 PM
	Levin Capital Strategies, L.P. Acquires 6,871 Shares of Fluidigm Co. (FLDM) Stock www.americanbankingnews.com - January 24 at 7:04 PM
	Daily Insider Ratings Round Up 1/11/18: Altisource, Fluidigm, China ... - Seeking Alpha seekingalpha.com - January 16 at 10:02 AM
	Levin Capital Strategies, L.P. Acquires 100,576 Shares of Fluidigm Co. (FLDM) Stock www.americanbankingnews.com - January 11 at 9:40 PM
	Fluidigm Co. (FLDM) Insider Acquires $66,706.20 in Stock www.americanbankingnews.com - January 2 at 7:32 PM
	ETFs with exposure to Fluidigm Corp. : January 1, 2018 finance.yahoo.com - January 1 at 4:47 PM
	Was Fluidigm Corporation’s (NASDAQ:FLDM) Earnings Growth Better Than Industry? finance.yahoo.com - December 30 at 9:49 AM
	Fluidigm Co. (FLDM) Insider Acquires $159,348.00 in Stock www.americanbankingnews.com - December 28 at 6:58 PM
	Fluidigm (FLDM) versus Castlight Health (CSLT) Financial Survey www.americanbankingnews.com - December 24 at 5:15 AM
	Fluidigm Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) finance.yahoo.com - December 21 at 4:53 PM
	ETFs with exposure to Fluidigm Corp. : December 19, 2017 finance.yahoo.com - December 19 at 4:50 PM
	Fluidigm Co. (FLDM) Insider Levin Capital Strategies, L.P. Acquires 24,175 Shares www.americanbankingnews.com - December 18 at 9:26 PM
	Fluidigm Co. (FLDM) Insider Buys $108,442.96 in Stock www.americanbankingnews.com - December 13 at 9:50 PM
	ETFs with exposure to Fluidigm Corp. : December 7, 2017 finance.yahoo.com - December 7 at 5:10 PM
	Insider Buying: Fluidigm Co. (FLDM) Insider Buys 8,409 Shares of Stock www.americanbankingnews.com - December 6 at 2:40 PM
	Cotiviti (COTV) & Fluidigm (FLDM) Critical Contrast www.americanbankingnews.com - December 6 at 7:36 AM
	Fluidigm (FLDM) versus Castlight Health (CSLT) Head to Head Review www.americanbankingnews.com - December 3 at 9:48 PM

Fluidigm (NASDAQ:FLDM) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Fluidigm (NASDAQ:FLDM) Income Statement, Balance Sheet and Cash Flow Statement

Fluidigm (NASDAQ FLDM) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff